Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 2, 2008, Pages 303-308

  Lal, Amar ^a   Bhurgri, Yasmin ^a   Rizvi, Nida ^a   Virwani, Mohni ^a   Memon, Rasheed Uddin ^a   Saeed, Wajeeha ^a   Sardar, MuhammadRizwan ^a   Kumar, Pawan ^a   Shaikh, Asim Jamal ^a   Adil, Salman ^a   Masood, Nehal ^a   Khurshed, Mohammed ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Cancer patients; Febrile neutropenia; In hospital stay; Mortality; Pakistan

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; FEMALE; FEVER; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; NEUTROPENIA; RISK FACTOR; STATISTICS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; FEVER; HEALTH CARE COSTS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 59849114052     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Althaus BL (2007). Myeloid growth factor therapy for prophylaxis of febrile neutropenia in non-myeloid malignancies: appropriate doses and schedules. J Natl Compr Canc Netw, 5, 229-34.
2. Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH (2005). Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol, 23, 7958-66.
3. Balducci L, Lyman GH (2001). Patients aged 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol, 19, 1583-5.
4. Bennett CL, Calhoun EA (2007). Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist, 12, 478-83.
5. Bennett CL, Schumock GT (2003). Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia: Can they improve clinical decision making? Drugs Aging, 20, 479-83.
6. Bhurgri Y (2004). Karachi cancer registry data - Implications in NCCP Pakistan. Asian Pac J Cancer Prev, 5, 86-91.
7. Caggiano V, Weiss RV, Rickert TS, et al (2005). Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 103, 1916-24.
8. Carbonero RC, Mayordomo JI, Tornamira MV, et al (2001). Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a Multicenter Randomized Trial. J Natl Cancer Inst, 93, 31-8.
9. Chrischilles E, Delgado DJ, Stolshek BS, et al (2002). Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non- Hodgkin's lymphoma. Cancer Control, 9, 203-11.
10. Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D (2007). Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perpective. Pharmacoeconomics, 25, 343- 51.
11. Hughes WT, Armstrong D, Bodey GP, et al (2002). 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis, 34, 730-51.
12. Khan MA, Siddiqui BK, Shamim A, et al (2004). Emerging bacterial resistance patterns in febrile neutropenic patients: experience at a tertiary care hospital in Pakistan. J Pak Med Assoc, 54, 357-60.
13. Klastersky J, Paesmans M, Rubenstein EJ, et al (2000). The Multinational Association for Supportive Care in Cancer Risk Index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol, 18, 3038-51.
14. Kuerer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006). Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 106, 2258-66.
15. Liou SY, Stephens JM, Carpiuc KT, Feng W (2007), Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Invest, 27, 381-96.
16. Lyman GH, Dale DC, Crawford J (2003). Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol, 21, 4524-31.
17. Lyman GH (2005). Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. J Natl Compr Canc Netw, 3, 557-71.
18. Malik IA, Khan WA, Karim M, Aziz Khan MA (1995). Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med, 98, 224-31.
19. Morrison VA, Picozzi V, Scott S, et al (2001). The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non- Hodgkin's lymphoma receiving initial CHOP chemotherapy: A risk factor analysis. Clin Lymphoma, 2, 47-56.
20. Ozer H, Armitage JO, Bennett CL, et al (2000). 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines - American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol, 18, 3558-85.
21. Ozer H (2006). The timing of chemotherapy-induced neutropenia and its clinical and economic impact. Oncology, 20 (5 Suppl 4), 11-5.
22. Rader M (2006). Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits. Oncology, 20(5 Suppl 4), 16-21.
23. Ray-Coquard I, Borg C, Bachelot T, Fayette J, Zufferey L (2006), Prognostic factors for febrile neutropenia. Bull Cancer, 93, 501-6.
24. Repetto L, Biganzoli L, Koehne CH, et al (2003). EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer, 39, 2264-72.
25. Shamsi TS, Irfan M, Ansari SH, et al (2004) Allogeneic peripheral blood stem cell transplantation in patients with haematological malignancies. J Coll Physicians Surg Pak, 14, 522-6.
26. Talcott JA, Finberg R, Mayer RJ, Goldman L (1988). The medical course of cancer patients with fever and neutropenia. Arch Intern Med, 148, 2561-8.
27. Timmer-Bonte JN, Adang EM, Smit HJ, Biesma B, Wilschut FA (2006). Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol, 24, 2975-7.
28. Vincenzino JV (1995) Health care costs: Market forces and reform. Oncology, 9, 367-368; 371- 74.
29. Weber RJ (1993). Pharmacoeconomic issues in the use of granulocyte-macrophage colony-stimulating factor for bone marrow transplantation or chemotherapy-induced neutropenia. Clin Ther, 15, 180-91.